(Q38428027)

3 September 2017

title

Efforts to support the development of fusidic acid in the United States (English)

1 reference

3 September 2017

author name string

Prabhavathi Fernandes

series ordinal

1

1 reference

3 September 2017

David Pereira

series ordinal

2

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

Clinical Infectious Diseases

3 September 2017

published in

1 reference

3 September 2017

volume

52 Suppl 7

1 reference

3 September 2017

page(s)

S542-6

1 reference

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

The antimicrobial activity of fusidic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Fusidic acid in vitro activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Fusidic-acid use and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Fusidic acid in bone and joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR170

21 January 2018

Identifiers

DOI

10.1093/CID/CIR170

1 reference

3 September 2017

1 reference